significance of keynote-189 in nsclc
Published 6 years ago • 253 plays • Length 5:33Download video MP4
Download video MP3
Similar videos
-
3:03
keynote-189 update: 4-year follow-up of fl pembro chemo metastatic nsclc
-
10:32
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:02
keynote-189: chemo plus pembrolizumab for nsclc
-
1:55
dr. kim on the keynote-189 trial in metastatic nsclc
-
4:53
chemo-immunotherapy in nsclc: the keynote-189 trial
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
2:25
dr. gadgeel on updated keynote-189 data in nsclc
-
6:11
nondriver nsclc trials: keynote-189, -407, -024
-
10:34
the keynote-189 trial for untreated metastatic nonsquamous nsclc
-
3:23
sequencing therapy in nsclc
-
4:21
optimizing use of the keynote-189 regimen in mnsclc
-
13:06
keynote-189: key summary of a practice-changing trial in advanced non-squamous nsclc (bmic-030)
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
2:57
keynote 189: targeting nsclc patients with brain and liver metastases
-
6:42
pembrolizumab in first-line nonsquamous nsclc
-
1:55
dr. rodriguez-abreu on the final analysis of the keynote-189 trial in nsclc
-
4:52
researcher comment: final analysis of keynote-189 | delvys rodriguez-abreu
-
6:32
keynote-189: clinical implications in patients with less than 1% tumor pd-l1 expression (bmic-033)
-
2:11
edward b. garon, md, on the implications of keynote-189